Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573780 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01573780 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT01573780, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and tolerated when given with gemcitabine hydrochloride to patients with advanced cancer
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER pharmacological study
- DRUG gemcitabine hydrochloride
- DRUG Smac mimetic TL32711
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573780
The ClinicalTrials.gov registry entry for NCT01573780 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01573780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01573780 about?
NCT01573780 is a clinical study titled "Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors". The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and tolerated when given with gemcitabine hydrochloride to patients with advanced cancer
What is the current status of trial NCT01573780?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2012-04.
What interventions are being tested in trial NCT01573780?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), pharmacological study (OTHER), gemcitabine hydrochloride (DRUG), Smac mimetic TL32711 (DRUG).
Who is sponsoring clinical trial NCT01573780?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.